Chapter title |
The Use of Anti-CD40 mAb in Cancer.
|
---|---|
Chapter number | 427 |
Book title |
Cancer Vaccines
|
Published in |
Current topics in microbiology and immunology, February 2015
|
DOI | 10.1007/82_2014_427 |
Pubmed ID | |
Book ISBNs |
978-3-31-923909-5, 978-3-31-923910-1
|
Authors |
Marcus Remer, Ann White, Martin Glennie, Aymen Al-Shamkhani, Peter Johnson, Remer, Marcus, White, Ann, Glennie, Martin, Al-Shamkhani, Aymen, Johnson, Peter |
Abstract |
Immunomodulatory monoclonal antibody (mAb) therapy is at the forefront of developing cancer therapeutics with numerous targeted agents proving highly effective in selective patients at stimulating protective host immunity, capable of eradicating established tumours and leading to long-term disease-free states. The cell surface marker CD40CD40 is expressed on a range of immune cells and transformed cells in malignant states whose signalling plays a critical role in modulating adaptive immune responses. Anti-CD40 mAbAnti-CD40 mAb therapy acts via multiple mechanisms to stimulate anti-tumour immunity across a broad range of lymphoid and solid malignancies. A wealth of preclinical research in this field has led to the successful development of multiple anti-CD40 mAb agents that have shown promise in early-phase clinical trials. Significant progress has been made to enhance the engagement of antibodies with immune effectors through their interactions with Fcγ receptors (FcγRs)Fcγ receptors (FcγRs) by the process of Fc engineering. As more is understood about how to best optimise these agents, principally through the fine-tuning of mAb structure and choice of synergistic partnerships, our ability to generate robust, clinically beneficial anti-tumour activity will form the foundation for the next generation of cancer therapeutics. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Belgium | 1 | 3% |
Unknown | 38 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 18% |
Researcher | 5 | 13% |
Other | 3 | 8% |
Student > Postgraduate | 3 | 8% |
Student > Master | 3 | 8% |
Other | 7 | 18% |
Unknown | 11 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Immunology and Microbiology | 7 | 18% |
Medicine and Dentistry | 7 | 18% |
Biochemistry, Genetics and Molecular Biology | 6 | 15% |
Agricultural and Biological Sciences | 2 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
Other | 1 | 3% |
Unknown | 14 | 36% |